(Incorporated in the Cayman Islands with limited liability) NOTIFICATION LETTER 通知信函 29 September 2025 Dear Non-registered Shareholder(s) (Note 1) , 華控康泰集團有限公司（「本公司」） Kontafarma China Holdings Limited (the "Company") — Notification of publication of 2025 Interim Report (the "Current Corporate Communication" (Note 2) ) The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.kontafarma.com.hk and the website of The Stock Exchange of Hong ...

Kontafarma China Holdings Limited (the "Company") — Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.kontafarma.com.hk and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corp ...

Financial Performance - Revenue for the six months ended June 30, 2025, was HK$452,723,000, a decrease of 1.7% from HK$458,517,000 in the same period of 2024[11]. - Gross profit for the same period was HK$254,621,000, down 8.1% from HK$277,146,000 year-on-year[11]. - Loss for the period attributable to owners of the company was HK$282,484,000, compared to a profit of HK$4,745,000 in the prior year[12]. - Total comprehensive expense for the period was HK$340,955,000, significantly higher than HK$1,215,000 in the previous year[12]. - Basic loss per share for the period was HK$5.06, compared to earnings of HK$0.09 per share in the prior year[12]. - The company reported a loss for the period of HK$282,484,000 for the six months ended June 30, 2025[17]. - The Group recorded a net loss of approximately HK$321.4 million for the six months ended June 30, 2025, a significant increase from a net loss of approximately HK$4.5 million in 2024[157]. Asset and Equity Changes - As of June 30, 2025, non-current assets decreased to HK$730,458,000 from HK$1,030,423,000 as of December 31, 2024, representing a decline of approximately 29.1%[14]. - Current assets totaled HK$422,582,000, down from HK$557,009,000 at the end of 2024, indicating a decrease of about 24.1%[15]. - Total equity attributable to owners decreased to HK$684,994,000 from HK$978,701,000, reflecting a decline of approximately 30.0%[15]. - Total segment assets as of June 30, 2025, were HK$1,133,923,000, a decrease from HK$1,524,600,000 as of December 31, 2024[44]. Impairment and Losses - Impairment losses recognized under the expected credit loss model amounted to HK$159,035,000, compared to HK$25,466,000 in the same period last year[11]. - Impairment loss on intangible assets increased to HK$123,873,000 in 2025 from HK$13,559,000 in 2024, reflecting a substantial rise[51]. - The Group recognized impairment losses of HK$161,282,000 on amounts due from an associate in 2025, compared to HK$22,565,000 in 2024, indicating a significant increase in credit risk[53]. - The impairment loss on goodwill was recorded at HK$88,417,000, reflecting a significant reduction from the carrying amount of HK$253,418,000 at the beginning of the year[75]. Cash Flow and Financing Activities - Net cash generated from operating activities for the six months ended June 30, 2025, was HK$53,014,000, compared to HK$50,434,000 for the same period in 2024, reflecting an increase of 3.1%[18]. - Net cash used in financing activities totaled HK$46,693,000, slightly down from HK$47,628,000 in the previous year, indicating a decrease of 2.0%[20]. - Cash and cash equivalents at the end of the period increased to HK$78,328,000 from HK$68,663,000, representing a growth of 14.4%[20]. - The Group's bank borrowings stood at HK$82,081,000 as of 30 June 2025, a decrease from HK$85,524,000 as of 31 December 2024[104]. Segment Performance - Pharmaceutical business revenue was HK$344,769,000, slightly down from HK$345,390,000, while fitness business revenue decreased to HK$107,954,000 from HK$113,127,000[37]. - The segment results for the pharmaceutical business showed a profit of HK$20,420,000, down from HK$60,478,000, while the fitness business reported a loss of HK$338,711,000 compared to a loss of HK$38,544,000 in the previous year[37]. - The decline in the fitness business was attributed to slower-than-expected recovery and operational difficulties faced by franchise operators in Taiwan[167]. Marketing and Strategic Initiatives - Increased marketing investment in the pharmaceutical segment led to higher distribution and selling expenses, impacting profitability[163]. - The Group plans to enhance marketing efficiency and intensify product research and development efforts in response to market competition[165]. - The Group's fitness business will strengthen digital marketing efforts to enhance brand image and customer acquisition[197]. - A series of initiatives will be launched, including more diverse membership packages and expanded private training courses, to enhance customer acquisition capabilities[197]. Legal Proceedings and Contingent Liabilities - As of June 30, 2025, the Group has contingent liabilities related to the 2019 Legal Proceedings and 2021 Legal Proceedings, with no material progress made during the interim period[128]. - The Group has been defending claims from Active Gains and Mr. PJW regarding a profit guarantee shortfall for the financial years 2017 and 2018, with 10,000 shares in True Cayman transferred to settle part of the amounts due[129]. - The 2019 Legal Proceedings involve a writ of summons regarding the acquisition of a 51% equity interest in TFKT True Holdings, with no trial date set as of the report date[130]. Employee and Compensation Information - Key management personnel compensation totaled HK$1,884,000 for the six months ended June 30, 2025, compared to HK$2,395,000 in the previous year[112]. - The Group had 655 employees, a decrease from 688 employees as of 31 December 2024[190]. - The share incentive plan aims to motivate selected employees and attract talent for the Group's growth and development[200].

(Incorporated in the Cayman Islands with limited liability) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Non-registered Shareholder(s) (Note 1) , Kontafarma China Holdings Limited (the "Company") — Notification of publication of the circular of discloseable and Connected transaction in relation to the construction contract for Beijing R&D complex (the "Current Corporate Communication" (Note 2) ) The English and Chinese versions of the Company's Current Corporate Communications are available on the Compan ...

(Incorporated in the Cayman Islands with limited liability) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Registered Shareholders, Kontafarma China Holdings Limited (the "Company") — Notice of publication of the circular of discloseable and Connected transaction in relation to the construction contract for Beijing R&D complex (the "Current Corporate Communication") If you for any reason have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 股東特別大會通告 茲通告華控康泰集團有限公司（「本公司」）謹訂於二零二五年十月二十日（星期一）上 午十時正假座香港灣仔謝斐道238號香港諾富特世紀酒店B3層宴會廳3號舉行股東 特別大會（「股東特別大會」）或其任何續會，藉以考慮並酌情通過（無論有否修訂）下 列決議案為本公司之普通決議案。除另有界定者外，本通告所用詞彙與本公司刊發 日期為二零二五年九月二十六日之通函中所定義者具有相同涵義。 普通決議案 「動議 (a) 全面批准、確認及追認本公司之直接全資附屬公司同方藥業集團有限公司（「同 方藥業」）（作為委託人）及北京清控中創工程建設有限公司（「北京清控」）（作為 承包商）所訂立日期為二零二五年八月十八日之建築合約（「北京建築合約」）， 據此同方藥業同意委聘北京清控作為總承包商以進行位於中國北京市延慶區八 達嶺鎮西康路2 3號的研發綜合樓及配套大門的建築工程，合約價為人民幣 33,672,360.58元（可 ...

為本公司股本中每股面值0.002港元股份 （附註二） 股之登記持有人， 股東特別大會代表委任表格 茲委任股東特別大會主席或 （附註三） 出席華控康泰集團有限公司（「本公司」）於二零二五年十月二十日（星期一）上午十時正在香港灣仔謝斐道238號香港諾富特世紀 酒店B3層宴會廳3號舉行之股東特別大會（「股東特別大會」）之代表委任表格： 地址為 本人╱吾等 （附註一） 地址為 為本人╱吾等之代表並以本人╱吾等名義出席股東特別大會（及其任何續會），並代表本人╱吾等行事，藉以考慮並酌情通過召 開股東特別大會通告（「通告」）所載之決議案（不論有否修訂），並於該股東特別大會（及其任何續會）以本人╱吾等名義，就該等 決議案按下文所載指示代表本人╱吾等投票。如無任何指示，則本人╱吾等之代表可酌情自行投票。 除另有界定者外，本代表委任表格所用之詞彙與本公司日期為二零二五年九月二十六日之通函所界定者具有相同涵義。 | | 普通決議案 | （附註五） 贊成 | （附註五） 反對 | | --- | --- | --- | --- | | (a) | 全面批准、確認及追認本公司之直接全資附屬公司同方藥業（作為委託 | | | | | 人 ...

此 乃 要 件 請 即 處 理 閣下如對本通函任何內容或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他持牌證 券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓所有名下之華控康泰集團有限公司股份，應立即將本通函送交買方或承讓 人，或經手出售或轉讓之銀行、股票經紀或其他持牌證券交易商或其他代理人，以便轉交買方或 承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 有關 北京研發綜合樓建築合約的 須予披露及關連交易 本封面頁所用詞彙與本通函所界定者具相同涵義。董事會函件載於本通函第4至10頁。 董事會函件載於本通函第4至10頁。獨立董事委員會致獨立股東之推薦意見函載於本通函第11至 12頁。載有獨立財務顧問旭倫企業融資有限公司就北京建築合約及其項下擬進行的交易致獨立 董事委員會及獨立股東之意見之函件載於本通函第13至22頁。 股東特別大會謹訂於二零二五年十月二十日（星期一）上午十時正假座香港灣仔謝斐道238號香港 諾富特 ...

延遲寄發 有關 須予披露及關連交易的通函 茲提述華控康泰集團有限公司（「本公司」）日期為二零二五年八月十八日的公告（「該 公告」），內容有關就北京研發綜合樓項目所訂立的北京建築合約。除另有界定者 外，本公告所用詞彙與該公告所界定者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 如該公告所述，一份載有（其中包括）(i)有關北京建築合約及其項下擬進行之交易的 進一步資料；(ii)獨立董事委員會向獨立股東提供的推薦建議；(iii)獨立財務顧問函 件，當中載有其有關上述事項的意見；及(iv)召開股東特別大會的通告連同代表委 任表格的通函（「該通函」），預期將於二零二五年九月八日或之前寄發予股東。 由於需要額外時間確定將載入該通函的若干資料，本公司正向聯交所申請豁免嚴格 遵守上市規則第14.41(a)條的規定，目前預期該通函的寄發日期將推遲至二零二五 年九月三十日或之前的日期。 承董事會命 華控康泰集團有限公司 主席 王飛飛 香港，二零二五年九 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華控康泰集團有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01312 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.002 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.002 | HKD | | 200,000,000 | ...